Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria

Infection and Immunity

Volumn 67, Issue 7, 1999, Pages 3680-3685

  Viret, Jean Francois ^a   Favre, Didier ^a   Wegmüller, Bernhard ^a   Herzog, Christian ^a   Que, John U ^a   Cryz Jr , Stanley J ^a   Lang, Alois B ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; TOXIN ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SALMONELLA TYPHI; VIBRIO CHOLERAE;

EID: 0033007238     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.7.3680-3685.1999     Document Type: Article

References (29)

1. Cancellieri, V., and G. M. Fara. 1985. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. J. Infect. Dis. 151:482-484.
2. Clements, J. D., F. VanLoon, D. A. Sack, et al. 1991. Field trial of cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163:1235-1242.
3. Clements, M. L., M. M. Levine, C. R. Young, et al. 1982. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:465-473.
4. Cryz, S. J., M. M. Levine, G. A. Losonsky, J. B. Kaper, and B. Althaus. 1992. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun. 60:3916-3917.
5. Cryz, S. J., J. U. Que, M. M. Levine, G. Wiedermann, and H. Kollaritsch. 1995. Safety and immunogenicity of a live oral bivalent typoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect. Immun. 63:1336-1339.
6. Czerkinsky, C., L.-A. Nilsson, H. Nygren, O. Ouchterlony, and A. Tarkowski. 1983. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. J. Immunol. Methods 65:109-121.
7. D'Amelio, R., A. Tagliabue, L. Nencioni, A. Di Addario, L. Villa, M. Manganaro, D. Boraschi, S. Le Moli, R. Nisini, and P. M. Matricardi. 1988. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect. Immun. 56:2731-2735.
8. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132:2736-2741.
9. Forrest, B. D., J. T. LaBrooy, P. Robinson, C. E. Dearlove, and D. J. C. Shearman. 1991. Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine. Infect. Immun. 59: 1206-1209.
10. Glass, R. I., A.-M. Svennerholm, M. R. Khan, S. Huda, M. I. Huq, and J. Holmgren. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242.
11. Kantele, A. 1990. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 8:321-326.
12. Kantele, A., and P. H. Mäkelä. 1991. Different profiles of human immune response to primary and secondary immunization with oral Salmonella typhi Ty21a vaccine. Vaccine 9:423-428.
13. Kantele, A., H. Arvilommi, J. M. Kantele, L. Rintala, and P. H. Mäkelä. 1991. Comparison of the human immune response to live oral, killed or killed parenteral Salmonella typhi Ty21a vaccine. Microb. Pathog. 10:117-126.
14. Kaper, J. B., J. G. Morris, and M. M. Levine. 1995. Cholera. Clin. Microbiol. Rev. 8:48-86.
15. Levine, M. M., D. R. Nalin, J. P. Craig, et al. 1979. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. 73:3-9.
16. Levine, M. M., C. R. Young, R. E. Black, Y. Takeda, and R. A. Finkelstein. 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21:174-179.
17. Levine, M. M., D. Herrington, G. Losonsky, et al. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467-470.
18. Losonsky, G. A., J. Yunyongying, V. Lim, M. Reymann, Y. L. Lim, S. S. Wasserman, and M. M. Levine. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:10-15.
19. Lycke, N., and J. Holmgren. 1986. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand. J. Immunol. 23:611-616.
20. Majumdar, A. S., P. Dutta, D. Dutta, and A. C. Ghose. 1981. Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infect. Immun. 32:1-8.
21. Marinaro, M., H. F. Staats, T. Hiroi, et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
22. Nandy, R. K., M. J. Albert, and A. C. Ghose. 1996. Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and evaluation of their importance in protection. Vaccine 14:1137-1142.
23. Sztein, M. B., S. S. Wasserman, C. O. Tacket, R. Edelman, D. Hone, A. A. Lindberg, and M. M. Levine. 1994. Cytokine production patterns and lymphoproliferative response in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170:1508-1517.
24. Sztein, M. B., M. K. Tanner, Y. Polotsky, J. M. Orenstein, and M. M. Levine. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:3987-3993.
25. Tacket, C. O., G. Losonsky, J. Nataro, et al. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:837-841.
26. Vajdy, M., and N. Lycke. 1992. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 75:488-492.
27. VanCott, J. L., H. F. Staats, D. W. Pascual, M. Roberts, S. N. Chatfield, M. Yamamoto, M. Coste, P. B. Carter, H. Kiyono, and J. R. McGhee. 1996. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J. Immunol. 156:1504-1514.
28. Viret, J.-F., and S. J. Cryz. 1995. Protective immunity induced by typhoid fever and vaccination. Southeast Asian J. Trop. Med. Public Health 26:150-159.
29. Wasserman, S. S., G. A. Losonsky, F. Noriega, C. O. Tacket, E. Castaneda, and M. M. Levine. 1994. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12:1000-1003.